nach oben

Journal of Neural Transmission

Erschienen in:

01.12.2009 | Movement Disorders - Short Communication

Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases

verfasst von: Tibor Kovács, Marianna Farsang, Edina Vitaszil, Péter Barsi, Tamás Györke, Imre Szirmai, Anita Kamondi

Erschienen in: Journal of Neural Transmission | Ausgabe 12/2009

Einloggen, um Zugang zu erhalten

Abstract

Levetiracetam (LEV) has been shown to suppress myoclonus of various origins. Corticobasal degeneration (CBD), a progressive neurodegenerative disorder with Parkinsonian syndrome, is frequently accompanied by myoclonus. We investigated the effect of LEV on myoclonus in two CBD patients. LEV remarkably decreased the myoclonic activity in both patients already at 1,500 mg/day dose. This is the first report on LEV alleviating myoclonus in CBD. Our data indicate that it might be worthwhile to assess this effect in an appropriately designed study.

Agarwal P, Frucht SJ (2003) Myoclonus. Curr Opin Neurol 16:515–521CrossRefPubMed

Beran RG, Berkovic SF, Black AB et al (2005) Efficacy of levetiracetam 1000–3000 mg/day in patients with refractory partial-onset seizures: a multicenter, open label single-arm study. Epilepsy Res 63:1–9CrossRefPubMed

Berkovic SF, Knowlton RC, Leroy RF, Schiemann J, Falter U, The Levetiracetam N01057 Study Group (2007) Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 69:1751–1760CrossRefPubMed

Boeve BF, Lamg AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54:S15–S19CrossRefPubMed

Crest C, Dupont S, Leguern E et al (2004) Levetiracetam in progressive myoclonic epilepsy. An exploratory study in 9 patients. Neurology 62:640–643PubMed

D’Amelio M, Callari G, Gammino M et al (2005) Levetiracetam in the treatment of vascular chorea: a case report. Eur J Clin Pharmacol 60:835–836CrossRefPubMed

de Tommaso M, di Fruscolo O, Sciruicchio V et al (2005) Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 28:280–284CrossRefPubMed

Fahn S (2002) Overview, history, and classification of myoclonus. Adv Neurol 89:13–17PubMed

Frucht S, Leurgans S, Hallet M et al (2000) The Unified Myoclonus Rating Scale (UMRS): a statistically validated clinical rating instrument for evaluating patients with myoclonus. Mov Disord 15(Suppl 3):107

Grisoli M, Fetoni V, Savoiardo M et al (1995) MRI in corticobasal degeneration. Eur J Neurol 2:547–552

Grosse P, Kühn A, Cordivari C, Brown P (2003) Coherence analysis in the myoclonus of corticobasal degeneration. Mov Disord 18:1345–1350CrossRefPubMed

Keswani SC, Kossoff EH, Krauss GL et al (2002) Amelioration of spinal myoclonus with levetiracetam. J Neurol Neurosurg Psychiatry 73:457–458CrossRefPubMed

Kompoliti K, Goetz CG, Boeve BF et al (1998) Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 55:957–961CrossRefPubMed

Krauss GL, Bergin MB, Kramer RE et al (2001) Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 56:411–412PubMed

Litvan I, Bhatia KP, Burn DJ et al (2003) SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18:467–486CrossRefPubMed

Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracteam. Proc Natl Acad Sci USA 101:9861–9866CrossRefPubMed

Lyons KE, Pahwa R (2006) Efficacy and tolerability of levetiracetam in Parkinson disease patients with levodopa-induced dyskinesia. Clin Neuropharmacol 29:148–153CrossRefPubMed

Margineanu DG, Klitgaard H (2000) Inhibition of neuronal hypersynchrony in vitro differentiates levetiracetam from classical antiepileptic drugs. Pharmacol Res 42:281–285CrossRefPubMed

Meco G, Fabrizio E, Epifanio A et al (2006) Levetiracetam in tardive dyskinesia. Clin Neuropharmacol 29:265–268CrossRefPubMed

Mima T, Nagamini T, Ikeda A et al (1998) Pathogenesis of cortical myoclonus studied by magnetoencephalography. Ann Neurol 43:598–607CrossRefPubMed

Riley DE, Lang AE, Lewis A et al (1990) Cortical-basal ganglionic degeneration. Neurology 40:1203–1212PubMed

Sawle GV, Brooks DJ, Marsden CD et al (1991) Corticobasal degeneration: a unique pattern of regional cortical oxygen metabolism and striatal fluorodopa uptake demonstrated by positron emission tomography. Brain 114:541–556CrossRefPubMed

Shibasaki H, Kuroiwa Y (1975) Electroencephalographic correlates of myoclonus. Electroencephalogr Clin Neurophysiol 36:455–463

Storey E, Lichtenstein M, Desmond P et al (1995) Clinical features and SPECT scanning in presumed corticobasal ganglionic degeneration. J Clin Neurosci 2:321–328CrossRefPubMed

Striano P, Manganelli F, Boccella P et al (2005) Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study. Mov Disord 20:1610–1614CrossRefPubMed

Thompson PD, Day BL, Rothwell JC et al (1994) The myoclonus in corticobasal degeneration. Brain 117:1197–1207CrossRefPubMed

Wadia PM, Lang AE (2007) The many faces of corticobasal degeneration. Parkinsonism Relat Disord 13:S336–S340CrossRefPubMed

Zesiewicz TA, Louis ED, Sulivan KL et al (2004) Substantial improvement in a Meige’s syndrome patient with levetiracteam treatment. Mov Disord 19:1518–1521CrossRefPubMed

Titel: Levetiracetam reduces myoclonus in corticobasal degeneration: report of two cases
verfasst von: Tibor Kovács
Marianna Farsang
Edina Vitaszil
Péter Barsi
Tamás Györke
Imre Szirmai
Anita Kamondi
Publikationsdatum: 01.12.2009
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 12/2009
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-009-0301-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2009

Chronic social isolation is related to both upregulation of plasticity genes and initiation of proapoptotic signaling in Wistar rat hippocampus

Motor excitability during imagination and observation of foot dorsiflexions

Arithmetic tasks in different formats and their influence on behavior and brain oxygenation as assessed with near-infrared spectroscopy (NIRS): a study involving primary and secondary school children

Increased d-amino acid oxidase expression in the bilateral hippocampal CA4 of schizophrenic patients: a post-mortem study

Methylphenidate treatment increases Na+, K+-ATPase activity in the cerebrum of young and adult rats

Elevated serum homocysteine level is not associated with serum C-reactive protein in patients with probable Alzheimer’s disease